Paul Bolno, Wave Life Sciences (Wave Life Sciences via Twitter)

Wave makes $100M pub­lic of­fer­ing af­ter dos­ing first sub­jects with GSK-part­nered RNA edit­ing drug

Wave Life Sci­ences is of­fer­ing $100 mil­lion in shares just short­ly af­ter it start­ed test­ing its first RNA edit­ing can­di­date in healthy sub­jects, which trig­gered a pay­out from Big Phar­ma part­ner GSK.

The biotech an­nounced the pub­lic of­fer­ing on Wednes­day, the same day it be­gan dos­ing healthy vol­un­teers with its al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD) treat­ment can­di­date, WVE-006. Wave’s RestorAA­Tion pro­gram com­pris­es two tri­als — RestorAA­Tion-1 is fo­cused on healthy sub­jects, and RestorAA­Tion-2 is en­rolling AATD pa­tients with a ho­mozy­gous PiZZ mu­ta­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.